Zacks analysts published research on 16 major stocks on October 12, 2026. Oracle faces headwinds from negative free cash flow and intense cloud competition but benefits from AI demand. American Express shows strong spending and customer acquisition despite rising expenses. Progressive maintains a neutral stance due to normalizing auto pricing and valuation concerns. Additional coverage includes Western Midstream, BrightSpring Health, and Dr. Reddy's Laboratories.

The global substance use disorder treatment market is projected to grow from $11.6 billion in 2025 to $14.6 billion by 2030, with a compound annual growth rate of 4.6%. Growth is driven by long-acting therapies, telemedicine expansion, drug innovation, and increased government interventions, though challenges include low treatment penetration and stigma.

Pomerantz LLP is investigating potential securities fraud claims against Dr. Reddy's Laboratories following the company's announcement of weak Q1 FY2027 earnings with only $0.06 EPS, attributed to a ₹2.4 billion provision for out-of-specification semaglutide batches. The disclosure triggered a 9.4% stock price decline on July 22, 2026.

Pomerantz LLP announced investigations into potential securities fraud at Emergent BioSolutions, Klarna Group, and Dr. Reddy's Laboratories. Emergent reported a $191.3 million impairment charge on its NARCAN asset group and cut full-year revenue guidance by 10.8%, citing increased competitive intensity. The stock fell 29.58% on the news.

The global papulopustular rosacea market is projected to grow steadily through 2035, driven by rising prevalence, improved diagnosis, and demand for safer non-antibiotic treatments. Advanced therapies including topical ivermectin, azelaic acid, and minocycline foam are reshaping care. Key players include Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories, with growth supported by dermatology R&D, innovative drug delivery, and telemedicine despite challenges like high treatment costs and underdiagnosis.

Law firm Kirby McInerney LLP is investigating potential securities fraud claims against Dr. Reddy's Laboratories following the company's disclosure of a ₹2.4 billion provision for out-of-spec semaglutide batches in Q1 FY2027 earnings. The stock fell 9% on the news, though management stated there was no patient safety impact or regulatory filing impact.

The global antiparasitic drugs market is projected to grow from USD 23.30 billion in 2026 to USD 30.98 billion by 2032 at a 4.88% CAGR. Growth is driven by persistent parasitic disease burden, drug resistance, climate-sensitive vector transmission, and public health programs. Key opportunities include resistance-ready combination therapies, pediatric formulations, AI-enabled discovery, and diagnostics-linked prescribing, with Africa and Asia-Pacific leading endemic demand.

The global generic drug market is projected to grow from USD 491.35 billion in 2024 to USD 926.54 billion by 2034, expanding at a CAGR of 6.55%. Growth is driven by increasing demand for cost-effective medicines, rising chronic diseases, and aging populations, particularly in North America and Asia-Pacific regions. However, the market faces challenges from low awareness, branded drug preference among practitioners, and limited rural distribution.

Following the expiration of India's semaglutide patent, over 40 Indian pharmaceutical companies have launched generic versions of Novo Nordisk's Ozempic and Wegovy at dramatically reduced prices—approximately 70% cheaper than originals. Major players like Sun Pharmaceutical, Dr. Reddy's Laboratories, and Zydus Lifesciences are offering monthly treatments ranging from $7.99 to $44.73, with plans to expand into global markets including Canada, Brazil, and Latin America as the obesity market is projected to reach $100 billion by decade's end.

The global tetracyclines market is experiencing steady growth at a CAGR of 5.23%, driven by broad-spectrum efficacy, cost-effectiveness, and expanding applications in respiratory infections, dermatology, and sexual health. Doxycycline dominates with 46.1% market share, while oral formulations lead with 64.0% share. Key growth drivers include rising antibiotic demand in veterinary and aquaculture sectors, emerging clinical applications like Doxy-PEP, and robust supply chains from China and India.

The FDA is considering expediting the review process for Eli Lilly's experimental oral weight-loss treatment, orforglipron, potentially moving the decision date to late March. Rival Novo Nordisk is preparing to launch its own weight-loss pill in December or January.

The Trump administration will exclude imported generic drugs from potential tariffs, bringing relief to pharmaceutical companies and Indian drugmakers who supply nearly half of U.S. generic prescriptions.